<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758524</url>
  </required_header>
  <id_info>
    <org_study_id>CLCI699A2201</org_study_id>
    <nct_id>NCT00758524</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a proof-of-efficacy, dose finding study of LCI699 in participants with&#xD;
      mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure&#xD;
      (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and&#xD;
      eplerenone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2008</start_date>
  <completion_date type="Actual">July 2, 2009</completion_date>
  <primary_completion_date type="Actual">July 2, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths</measure>
    <time_frame>AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks</time_frame>
    <description>An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8</measure>
    <time_frame>Baseline, every hour up to 24 hours post-dose at Week 8</time_frame>
    <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8</measure>
    <time_frame>Baseline, every hour up to 24 hours post-dose at Week 8</time_frame>
    <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MSDBP response was defined as the percentage of participants with a MSDBP &lt;90 mmHg or a &gt;=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP &lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MSSBP response was defined as the percentage of participants with a MSSBP &lt;140 mmHg or a &gt;=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP &lt;140 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test</measure>
    <time_frame>Baseline, 1 hour post-dose at Week 8</time_frame>
    <description>The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was &lt;500 nanomoles per liter (nmol/L) at 1 hour after the injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP</measure>
    <time_frame>From Week 8 to Week 9</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP</measure>
    <time_frame>From Week 8 to Week 9</time_frame>
    <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">628</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Core Period: LCI699 0.25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Period: LCI699 0.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Period: LCI699 1.0 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Period: LCI699 0.5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Period: Eplerenone 50 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core Period: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.25 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 1.0 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 1.0 mg QD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg BID Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: Eplerenone 50 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: Eplerenone 50 mg BID Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Period: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCI699</intervention_name>
    <description>LCI699 oral capsules</description>
    <arm_group_label>Core Period: LCI699 0.25 mg QD</arm_group_label>
    <arm_group_label>Core Period: LCI699 0.5 mg BID</arm_group_label>
    <arm_group_label>Core Period: LCI699 0.5 mg QD</arm_group_label>
    <arm_group_label>Core Period: LCI699 1.0 mg QD</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.25 mg QD</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg BID</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg QD</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 1.0 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone oral capsules</description>
    <arm_group_label>Core Period: Eplerenone 50 mg BID</arm_group_label>
    <arm_group_label>Withdrawal Period: Eplerenone 50 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCI699-matching Placebo</intervention_name>
    <description>LCI699-matching placebo oral capsules</description>
    <arm_group_label>Core Period: Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.25 mg QD Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg BID Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 0.5 mg QD Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: LCI699 1.0 mg QD Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone-matching Placebo</intervention_name>
    <description>Eplerenone-matching placebo oral capsules</description>
    <arm_group_label>Core Period: Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: Eplerenone 50 mg BID Placebo</arm_group_label>
    <arm_group_label>Withdrawal Period: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and non-fertile females.&#xD;
&#xD;
          -  18-75 years inclusive.&#xD;
&#xD;
          -  Participants with mild-to-moderate uncomplicated essential hypertension.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All women of child bearing potential.&#xD;
&#xD;
          -  Female participants on hormone replacement therapy.&#xD;
&#xD;
          -  Severe hypertension.&#xD;
&#xD;
          -  History or evidence of a secondary form of hypertension.&#xD;
&#xD;
          -  Known moderate or malignant retinopathy.&#xD;
&#xD;
          -  History of angina pectoris, myocardial infarction, coronary bypass surgery,ischemic&#xD;
             heart disease, surgical or percutaneous arterial intervention of any kind (coronary,&#xD;
             carotid or peripheral vessels), stroke, transient ischemic attack (TIA), carotid&#xD;
             artery stenosis, aortic aneurysm or peripheral arterial disease.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
          -  Clinically significant valvular heart disease.&#xD;
&#xD;
          -  Congestive heart failure (New York Heart Association [NYHA] class II-IV).&#xD;
&#xD;
          -  Cardiac electrical abnormalities indicating significant risk of safety for participant&#xD;
             taking part in the study.&#xD;
&#xD;
          -  History of malignancy of any organ system, treated or untreated, within the past 5&#xD;
             years.&#xD;
&#xD;
          -  Liver disease such as cirrhosis or chronic active hepatitis.&#xD;
&#xD;
          -  Any surgical or medical conditions that may significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of any drug substance&#xD;
&#xD;
          -  Any surgical or medical conditions, not identified in the protocol that in the opinion&#xD;
             of the investigator or the monitor, place the participant at higher risk from his/her&#xD;
             participation in the study, or is likely to prevent the participant from complying&#xD;
             with the requirements of the study or completing the trial period.&#xD;
&#xD;
          -  Participant unwilling or not able to discontinue safely the use of current&#xD;
             antihypertensive medications during the study period&#xD;
&#xD;
          -  Any contraindication or history of hypersensitivity to any of the study drugs or to&#xD;
             drugs with similar chemical structures.&#xD;
&#xD;
          -  Chronic oral or parenteral corticosteroid treatment.&#xD;
&#xD;
          -  Treatment with potassium supplement or potassium sparing diuretics.&#xD;
&#xD;
          -  Treatment with potent cytochrome P450 3A4 (CYP3A4) inhibitors during the study period.&#xD;
&#xD;
          -  Use of other investigational drugs at Visit 1, or within 30 days or 5 half-lives of&#xD;
             Visit 1, whichever is longer, unless local health authority guidelines mandate a&#xD;
             longer period.&#xD;
&#xD;
          -  Serum potassium &gt; 5.2 milliequivalents per liter (mEq/L) or &lt; 3.5 mEq/L at Visit 1.&#xD;
&#xD;
          -  Serum sodium &lt; 132 mEq/L at Visit 1.&#xD;
&#xD;
          -  Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) &gt; 2 times the upper&#xD;
             limit of the normal range (ULN) at Visit 1.&#xD;
&#xD;
          -  Bilirubin (total) &gt; 1.5 x ULN at Visit 1.&#xD;
&#xD;
          -  Modification of diet in renal disease estimated glomerular filtration rate (MDRD eGFR)&#xD;
             &lt; 60 milliliters per minute (ml/min)/1.73 m^2 at Visit 1.&#xD;
&#xD;
          -  Other clinically significant laboratory abnormalities, confirmed by repeat&#xD;
             measurements, at Visit 1.&#xD;
&#xD;
          -  History of active substance abuse (including alcohol).&#xD;
&#xD;
          -  Participants with night-shift employment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>May 17, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2021</results_first_posted>
  <disposition_first_submitted>May 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 6, 2012</disposition_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Phase 2 study</keyword>
  <keyword>Antihypertensive agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part at 84 investigative sites in Argentina, Australia, France, Germany, Netherlands, Romania, Spain, Sweden, and the United States from 11 September 2008 to 02 July 2009.</recruitment_details>
      <pre_assignment_details>A total of 628 participants were enrolled in the study. Out of 628, only 524 participants with essential hypertension were randomized to receive LCI699 or eplerenone in comparison with placebo for 8 weeks, followed by a randomized withdrawal period to either continue the treatment arm they were randomized to or to take placebo for one additional week (Week 9).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Core Period: LCI699 0.25 mg QD</title>
          <description>Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Core Period: LCI699 0.5 mg QD</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Core Period: LCI699 1.0 mg QD</title>
          <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Core Period: LCI699 0.5 mg BID</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Core Period: Eplerenone 50 mg BID</title>
          <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Core Period: Placebo</title>
          <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Withdrawal Period: LCI699 0.25 mg QD</title>
          <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P8">
          <title>Withdrawal Period: LCI699 0.25 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P9">
          <title>Withdrawal Period: LCI699 0.5 mg QD</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P10">
          <title>Withdrawal Period: LCI699 0.5 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P11">
          <title>Withdrawal Period: LCI699 1.0 mg QD</title>
          <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P12">
          <title>Withdrawal Period: LCI699 1.0 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P13">
          <title>Withdrawal Period: LCI699 0.5 mg BID</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P14">
          <title>Withdrawal Period: LCI699 0.5 mg BID Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P15">
          <title>Withdrawal Period: Eplerenone 50 mg BID</title>
          <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P16">
          <title>Withdrawal Period: Eplerenone 50 mg BID Placebo</title>
          <description>Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="P17">
          <title>Withdrawal Period: Placebo</title>
          <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Period (Week 0 to Week 8)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="97">One participant in this arm group was randomized twice and was excluded from Full Analysis Set.</participants>
                <participants group_id="P5" count="84"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="87">One participant from LCI699 0.5 mg QD was randomized to LCI699 1.0 mg QD and received LCI699 1.0 mg QD, thus was included in this arm in the Safety Set.</participants>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="84"/>
                <participants group_id="P6" count="76"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="67"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure Results</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Withdrawal Period (Week 8 to Week 9)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="46"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="44"/>
                <participants group_id="P10" count="37">One participant randomized to Placebo arm in Withdrawal Period received LCI699 0.5 mg QD and was counted in LCI699 0.5 mg QD arm in the Randomized Withdrawal Safety Set.</participants>
                <participants group_id="P11" count="41"/>
                <participants group_id="P12" count="37">One participant randomized to LCI699 0.5 mg BID in the core period received LCI699 1.0 mg QD and was considered in the LCI699 1.0 mg QD arm in Randomized Withdrawal Safety Set.</participants>
                <participants group_id="P13" count="45"/>
                <participants group_id="P14" count="45"/>
                <participants group_id="P15" count="39"/>
                <participants group_id="P16" count="36"/>
                <participants group_id="P17" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized Withdrawal Set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="45"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="43"/>
                <participants group_id="P10" count="37"/>
                <participants group_id="P11" count="41"/>
                <participants group_id="P12" count="36"/>
                <participants group_id="P13" count="45"/>
                <participants group_id="P14" count="44"/>
                <participants group_id="P15" count="39"/>
                <participants group_id="P16" count="36"/>
                <participants group_id="P17" count="67">One participant randomized to Placebo arm in Withdrawal Period received LCI699 0.5 mg QD and was counted in LCI699 0.5 mg QD arm in the Randomized Withdrawal Safety Set. However, this participant was counted in the Placebo arm (N=67) in the Randomized Withdrawal Set.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="45"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="42"/>
                <participants group_id="P10" count="37"/>
                <participants group_id="P11" count="41"/>
                <participants group_id="P12" count="37"/>
                <participants group_id="P13" count="45"/>
                <participants group_id="P14" count="45"/>
                <participants group_id="P15" count="39"/>
                <participants group_id="P16" count="36"/>
                <participants group_id="P17" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.</population>
      <group_list>
        <group group_id="B1">
          <title>Core Period: LCI699 0.25 mg QD</title>
          <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Core Period: LCI699 0.5 mg QD</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Core Period: LCI699 1.0 mg QD</title>
          <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Core Period: LCI699 0.5 mg BID</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Core Period: Eplerenone 50 mg BID</title>
          <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Core Period: Placebo</title>
          <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="86"/>
            <count group_id="B4" value="96"/>
            <count group_id="B5" value="84"/>
            <count group_id="B6" value="77"/>
            <count group_id="B7" value="522"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="92"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="86"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="84"/>
                    <count group_id="B6" value="77"/>
                    <count group_id="B7" value="522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="10.5"/>
                    <measurement group_id="B2" value="54.8" spread="7.8"/>
                    <measurement group_id="B3" value="54.5" spread="9.7"/>
                    <measurement group_id="B4" value="54.4" spread="10.8"/>
                    <measurement group_id="B5" value="55.3" spread="9.1"/>
                    <measurement group_id="B6" value="53.9" spread="8.7"/>
                    <measurement group_id="B7" value="54.5" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="92"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="86"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="84"/>
                    <count group_id="B6" value="77"/>
                    <count group_id="B7" value="522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <description>Ambulatory blood pressure monitoring (ABPM) measured a participant's blood pressure (BP) over 24-hour period readings using an automated validated monitoring device at Baseline. The 24-hour ambulatory DBP and 24-hour ambulatory SBP were calculated by taking the mean of all ambulatory DBP and SBP readings respectively for the 24-hour period.</description>
          <population>Only participants with available ABPM measurements were included for assessment of 24-hour ambulatory DBP and 24-hour SBP.</population>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Clinic Systolic Blood Pressure (SBP)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="92"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="86"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="84"/>
                    <count group_id="B6" value="77"/>
                    <count group_id="B7" value="522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.72" spread="12.163"/>
                    <measurement group_id="B2" value="157.04" spread="11.580"/>
                    <measurement group_id="B3" value="159.24" spread="10.415"/>
                    <measurement group_id="B4" value="158.50" spread="11.028"/>
                    <measurement group_id="B5" value="158.20" spread="10.954"/>
                    <measurement group_id="B6" value="156.69" spread="10.121"/>
                    <measurement group_id="B7" value="157.93" spread="11.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinic Diastolic Blood pressure (DBP)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="92"/>
                    <count group_id="B2" value="87"/>
                    <count group_id="B3" value="86"/>
                    <count group_id="B4" value="96"/>
                    <count group_id="B5" value="84"/>
                    <count group_id="B6" value="77"/>
                    <count group_id="B7" value="522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.43" spread="3.884"/>
                    <measurement group_id="B2" value="99.94" spread="3.314"/>
                    <measurement group_id="B3" value="100.03" spread="3.580"/>
                    <measurement group_id="B4" value="100.21" spread="3.450"/>
                    <measurement group_id="B5" value="100.39" spread="3.607"/>
                    <measurement group_id="B6" value="100.54" spread="3.814"/>
                    <measurement group_id="B7" value="100.25" spread="3.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hour Ambulatory SBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="76"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="78"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="66"/>
                    <count group_id="B7" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.97" spread="11.167"/>
                    <measurement group_id="B2" value="140.08" spread="13.502"/>
                    <measurement group_id="B3" value="143.85" spread="11.613"/>
                    <measurement group_id="B4" value="142.20" spread="11.079"/>
                    <measurement group_id="B5" value="143.30" spread="13.989"/>
                    <measurement group_id="B6" value="142.07" spread="13.150"/>
                    <measurement group_id="B7" value="142.25" spread="12.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hour Ambulatory DBP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="76"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="78"/>
                    <count group_id="B5" value="71"/>
                    <count group_id="B6" value="66"/>
                    <count group_id="B7" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.13" spread="8.893"/>
                    <measurement group_id="B2" value="89.33" spread="8.208"/>
                    <measurement group_id="B3" value="91.38" spread="7.998"/>
                    <measurement group_id="B4" value="90.81" spread="8.260"/>
                    <measurement group_id="B5" value="91.14" spread="8.861"/>
                    <measurement group_id="B6" value="90.11" spread="10.439"/>
                    <measurement group_id="B7" value="90.49" spread="8.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.47" spread="0.60"/>
                    <measurement group_id="O2" value="-5.50" spread="0.57"/>
                    <measurement group_id="O3" value="-7.11" spread="0.88"/>
                    <measurement group_id="O4" value="-4.25" spread="0.95"/>
                    <measurement group_id="O5" value="-7.49" spread="0.97"/>
                    <measurement group_id="O6" value="-3.22" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" spread="1.40"/>
                    <measurement group_id="O2" value="-10.69" spread="0.98"/>
                    <measurement group_id="O3" value="-11.93" spread="1.44"/>
                    <measurement group_id="O4" value="-9.10" spread="1.45"/>
                    <measurement group_id="O5" value="-13.31" spread="1.48"/>
                    <measurement group_id="O6" value="-2.93" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths</title>
        <description>An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.</description>
        <time_frame>AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks</time_frame>
        <population>Safety Set included all the participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths</title>
          <description>An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.</description>
          <population>Safety Set included all the participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.47" spread="0.60"/>
                    <measurement group_id="O2" value="-5.50" spread="0.57"/>
                    <measurement group_id="O3" value="-7.11" spread="0.88"/>
                    <measurement group_id="O4" value="-4.25" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" spread="1.40"/>
                    <measurement group_id="O2" value="-10.69" spread="0.98"/>
                    <measurement group_id="O3" value="-11.93" spread="1.44"/>
                    <measurement group_id="O4" value="-9.10" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)</title>
        <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants signifies the number of participants in the FAS who have a Baseline and a Week 8 mean 24-hour ABPM sitting SBP assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)</title>
          <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants signifies the number of participants in the FAS who have a Baseline and a Week 8 mean 24-hour ABPM sitting SBP assessment.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.15" spread="1.20"/>
                    <measurement group_id="O2" value="-4.90" spread="1.22"/>
                    <measurement group_id="O3" value="-7.73" spread="1.13"/>
                    <measurement group_id="O4" value="-6.18" spread="1.14"/>
                    <measurement group_id="O5" value="-10.52" spread="1.25"/>
                    <measurement group_id="O6" value="1.11" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM</title>
        <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants signifies the number of participants in the FAS who have a Baseline and a Week 8 mean 24-hour ABPM sitting DBP assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM</title>
          <description>An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants signifies the number of participants in the FAS who have a Baseline and a Week 8 mean 24-hour ABPM sitting DBP assessment.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.03" spread="0.91"/>
                    <measurement group_id="O2" value="-2.44" spread="0.92"/>
                    <measurement group_id="O3" value="-4.96" spread="0.86"/>
                    <measurement group_id="O4" value="-2.75" spread="0.86"/>
                    <measurement group_id="O5" value="-6.03" spread="0.94"/>
                    <measurement group_id="O6" value="1.03" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8</title>
        <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
        <time_frame>Baseline, every hour up to 24 hours post-dose at Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8</title>
          <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8, Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="1.466"/>
                    <measurement group_id="O2" value="2.95" spread="1.541"/>
                    <measurement group_id="O3" value="0.27" spread="1.389"/>
                    <measurement group_id="O4" value="3.87" spread="1.404"/>
                    <measurement group_id="O5" value="0.17" spread="1.544"/>
                    <measurement group_id="O6" value="7.11" spread="1.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.452"/>
                    <measurement group_id="O2" value="1.85" spread="1.488"/>
                    <measurement group_id="O3" value="0.17" spread="1.397"/>
                    <measurement group_id="O4" value="3.44" spread="1.381"/>
                    <measurement group_id="O5" value="-1.65" spread="1.529"/>
                    <measurement group_id="O6" value="6.28" spread="1.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.477"/>
                    <measurement group_id="O2" value="1.13" spread="1.502"/>
                    <measurement group_id="O3" value="-0.36" spread="1.387"/>
                    <measurement group_id="O4" value="4.01" spread="1.369"/>
                    <measurement group_id="O5" value="-2.42" spread="1.528"/>
                    <measurement group_id="O6" value="4.99" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.452"/>
                    <measurement group_id="O2" value="2.91" spread="1.488"/>
                    <measurement group_id="O3" value="0.35" spread="1.386"/>
                    <measurement group_id="O4" value="2.64" spread="1.378"/>
                    <measurement group_id="O5" value="-1.39" spread="1.541"/>
                    <measurement group_id="O6" value="7.02" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.463"/>
                    <measurement group_id="O2" value="-0.02" spread="1.513"/>
                    <measurement group_id="O3" value="-1.69" spread="1.385"/>
                    <measurement group_id="O4" value="1.45" spread="1.377"/>
                    <measurement group_id="O5" value="-2.91" spread="1.514"/>
                    <measurement group_id="O6" value="4.31" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.451"/>
                    <measurement group_id="O2" value="-2.36" spread="1.487"/>
                    <measurement group_id="O3" value="-3.01" spread="1.386"/>
                    <measurement group_id="O4" value="1.20" spread="1.367"/>
                    <measurement group_id="O5" value="-4.86" spread="1.513"/>
                    <measurement group_id="O6" value="1.82" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.463"/>
                    <measurement group_id="O2" value="-0.95" spread="1.487"/>
                    <measurement group_id="O3" value="-2.63" spread="1.406"/>
                    <measurement group_id="O4" value="1.21" spread="1.366"/>
                    <measurement group_id="O5" value="-3.70" spread="1.513"/>
                    <measurement group_id="O6" value="3.62" spread="1.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.01" spread="1.464"/>
                    <measurement group_id="O2" value="-1.38" spread="1.487"/>
                    <measurement group_id="O3" value="-2.43" spread="1.396"/>
                    <measurement group_id="O4" value="2.09" spread="1.366"/>
                    <measurement group_id="O5" value="-2.30" spread="1.514"/>
                    <measurement group_id="O6" value="2.65" spread="1.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="1.464"/>
                    <measurement group_id="O2" value="-0.07" spread="1.487"/>
                    <measurement group_id="O3" value="-2.25" spread="1.386"/>
                    <measurement group_id="O4" value="3.27" spread="1.366"/>
                    <measurement group_id="O5" value="-2.81" spread="1.515"/>
                    <measurement group_id="O6" value="3.30" spread="1.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="1.452"/>
                    <measurement group_id="O2" value="2.60" spread="1.487"/>
                    <measurement group_id="O3" value="-1.65" spread="1.385"/>
                    <measurement group_id="O4" value="0.49" spread="1.378"/>
                    <measurement group_id="O5" value="-2.43" spread="1.515"/>
                    <measurement group_id="O6" value="3.86" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="1.451"/>
                    <measurement group_id="O2" value="1.72" spread="1.487"/>
                    <measurement group_id="O3" value="-1.54" spread="1.386"/>
                    <measurement group_id="O4" value="1.54" spread="1.367"/>
                    <measurement group_id="O5" value="-1.93" spread="1.514"/>
                    <measurement group_id="O6" value="2.38" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="1.451"/>
                    <measurement group_id="O2" value="2.53" spread="1.487"/>
                    <measurement group_id="O3" value="-3.10" spread="1.385"/>
                    <measurement group_id="O4" value="-1.06" spread="1.367"/>
                    <measurement group_id="O5" value="-3.20" spread="1.527"/>
                    <measurement group_id="O6" value="3.24" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.32" spread="1.451"/>
                    <measurement group_id="O2" value="-1.20" spread="1.487"/>
                    <measurement group_id="O3" value="-5.31" spread="1.385"/>
                    <measurement group_id="O4" value="-1.45" spread="1.366"/>
                    <measurement group_id="O5" value="-5.35" spread="1.513"/>
                    <measurement group_id="O6" value="1.52" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.47" spread="1.451"/>
                    <measurement group_id="O2" value="-3.29" spread="1.487"/>
                    <measurement group_id="O3" value="-7.38" spread="1.385"/>
                    <measurement group_id="O4" value="-2.96" spread="1.376"/>
                    <measurement group_id="O5" value="-7.64" spread="1.513"/>
                    <measurement group_id="O6" value="-0.90" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.34" spread="1.452"/>
                    <measurement group_id="O2" value="-5.82" spread="1.488"/>
                    <measurement group_id="O3" value="-8.89" spread="1.386"/>
                    <measurement group_id="O4" value="-6.10" spread="1.377"/>
                    <measurement group_id="O5" value="-9.03" spread="1.527"/>
                    <measurement group_id="O6" value="-1.01" spread="1.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.92" spread="1.465"/>
                    <measurement group_id="O2" value="-8.37" spread="1.491"/>
                    <measurement group_id="O3" value="-10.50" spread="1.387"/>
                    <measurement group_id="O4" value="-9.54" spread="1.369"/>
                    <measurement group_id="O5" value="-12.55" spread="1.528"/>
                    <measurement group_id="O6" value="-1.61" spread="1.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.26" spread="1.454"/>
                    <measurement group_id="O2" value="-10.99" spread="1.492"/>
                    <measurement group_id="O3" value="-12.71" spread="1.398"/>
                    <measurement group_id="O4" value="-10.38" spread="1.380"/>
                    <measurement group_id="O5" value="-12.88" spread="1.516"/>
                    <measurement group_id="O6" value="-4.20" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.68" spread="1.456"/>
                    <measurement group_id="O2" value="-11.73" spread="1.492"/>
                    <measurement group_id="O3" value="-11.88" spread="1.389"/>
                    <measurement group_id="O4" value="-11.85" spread="1.379"/>
                    <measurement group_id="O5" value="-13.49" spread="1.529"/>
                    <measurement group_id="O6" value="-6.89" spread="1.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.13" spread="1.456"/>
                    <measurement group_id="O2" value="-10.12" spread="1.493"/>
                    <measurement group_id="O3" value="-9.74" spread="1.388"/>
                    <measurement group_id="O4" value="-10.78" spread="1.369"/>
                    <measurement group_id="O5" value="-10.13" spread="1.517"/>
                    <measurement group_id="O6" value="-5.84" spread="1.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.73" spread="1.454"/>
                    <measurement group_id="O2" value="-8.06" spread="1.504"/>
                    <measurement group_id="O3" value="-10.43" spread="1.408"/>
                    <measurement group_id="O4" value="-10.49" spread="1.369"/>
                    <measurement group_id="O5" value="-10.47" spread="1.516"/>
                    <measurement group_id="O6" value="-5.21" spread="1.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.31" spread="1.453"/>
                    <measurement group_id="O2" value="-7.68" spread="1.489"/>
                    <measurement group_id="O3" value="-9.66" spread="1.386"/>
                    <measurement group_id="O4" value="-8.22" spread="1.377"/>
                    <measurement group_id="O5" value="-10.51" spread="1.514"/>
                    <measurement group_id="O6" value="-4.12" spread="1.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.90" spread="1.452"/>
                    <measurement group_id="O2" value="-4.93" spread="1.487"/>
                    <measurement group_id="O3" value="-5.37" spread="1.385"/>
                    <measurement group_id="O4" value="-6.35" spread="1.386"/>
                    <measurement group_id="O5" value="-7.60" spread="1.513"/>
                    <measurement group_id="O6" value="-1.09" spread="1.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="1.475"/>
                    <measurement group_id="O2" value="-1.93" spread="1.487"/>
                    <measurement group_id="O3" value="-1.18" spread="1.385"/>
                    <measurement group_id="O4" value="-2.67" spread="1.377"/>
                    <measurement group_id="O5" value="-5.54" spread="1.513"/>
                    <measurement group_id="O6" value="1.82" spread="1.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="1.477"/>
                    <measurement group_id="O2" value="1.45" spread="1.501"/>
                    <measurement group_id="O3" value="0.29" spread="1.397"/>
                    <measurement group_id="O4" value="1.36" spread="1.370"/>
                    <measurement group_id="O5" value="-2.78" spread="1.529"/>
                    <measurement group_id="O6" value="1.98" spread="1.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8</title>
        <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
        <time_frame>Baseline, every hour up to 24 hours post-dose at Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8</title>
          <description>Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8, Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="1.767"/>
                    <measurement group_id="O2" value="0.09" spread="1.859"/>
                    <measurement group_id="O3" value="-4.51" spread="1.674"/>
                    <measurement group_id="O4" value="-1.42" spread="1.690"/>
                    <measurement group_id="O5" value="-5.33" spread="1.863"/>
                    <measurement group_id="O6" value="8.23" spread="1.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.752"/>
                    <measurement group_id="O2" value="0.15" spread="1.795"/>
                    <measurement group_id="O3" value="-3.56" spread="1.685"/>
                    <measurement group_id="O4" value="-0.57" spread="1.663"/>
                    <measurement group_id="O5" value="-5.90" spread="1.844"/>
                    <measurement group_id="O6" value="6.48" spread="1.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.781"/>
                    <measurement group_id="O2" value="-1.53" spread="1.811"/>
                    <measurement group_id="O3" value="-4.86" spread="1.672"/>
                    <measurement group_id="O4" value="0.91" spread="1.649"/>
                    <measurement group_id="O5" value="-5.89" spread="1.843"/>
                    <measurement group_id="O6" value="4.60" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.752"/>
                    <measurement group_id="O2" value="-1.18" spread="1.794"/>
                    <measurement group_id="O3" value="-4.15" spread="1.672"/>
                    <measurement group_id="O4" value="1.50" spread="1.661"/>
                    <measurement group_id="O5" value="-5.12" spread="1.859"/>
                    <measurement group_id="O6" value="4.68" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.29" spread="1.766"/>
                    <measurement group_id="O2" value="-3.09" spread="1.825"/>
                    <measurement group_id="O3" value="-3.47" spread="1.671"/>
                    <measurement group_id="O4" value="-1.70" spread="1.660"/>
                    <measurement group_id="O5" value="-7.22" spread="1.826"/>
                    <measurement group_id="O6" value="2.78" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.21" spread="1.751"/>
                    <measurement group_id="O2" value="-3.12" spread="1.794"/>
                    <measurement group_id="O3" value="-5.88" spread="1.672"/>
                    <measurement group_id="O4" value="-1.02" spread="1.648"/>
                    <measurement group_id="O5" value="-7.91" spread="1.826"/>
                    <measurement group_id="O6" value="1.42" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.95" spread="1.766"/>
                    <measurement group_id="O2" value="-2.10" spread="1.794"/>
                    <measurement group_id="O3" value="-5.40" spread="1.697"/>
                    <measurement group_id="O4" value="-0.76" spread="1.649"/>
                    <measurement group_id="O5" value="-8.70" spread="1.826"/>
                    <measurement group_id="O6" value="2.25" spread="1.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.28" spread="1.766"/>
                    <measurement group_id="O2" value="-4.69" spread="1.794"/>
                    <measurement group_id="O3" value="-5.30" spread="1.684"/>
                    <measurement group_id="O4" value="-3.02" spread="1.649"/>
                    <measurement group_id="O5" value="-8.06" spread="1.827"/>
                    <measurement group_id="O6" value="3.76" spread="1.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.98" spread="1.766"/>
                    <measurement group_id="O2" value="-1.59" spread="1.795"/>
                    <measurement group_id="O3" value="-4.78" spread="1.672"/>
                    <measurement group_id="O4" value="-1.87" spread="1.649"/>
                    <measurement group_id="O5" value="-7.46" spread="1.828"/>
                    <measurement group_id="O6" value="2.39" spread="1.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="1.752"/>
                    <measurement group_id="O2" value="-0.30" spread="1.794"/>
                    <measurement group_id="O3" value="-3.40" spread="1.672"/>
                    <measurement group_id="O4" value="-1.73" spread="1.662"/>
                    <measurement group_id="O5" value="-7.35" spread="1.828"/>
                    <measurement group_id="O6" value="2.54" spread="1.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="1.751"/>
                    <measurement group_id="O2" value="-0.43" spread="1.795"/>
                    <measurement group_id="O3" value="-4.22" spread="1.672"/>
                    <measurement group_id="O4" value="-1.74" spread="1.649"/>
                    <measurement group_id="O5" value="-5.75" spread="1.827"/>
                    <measurement group_id="O6" value="3.51" spread="1.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.19" spread="1.752"/>
                    <measurement group_id="O2" value="0.73" spread="1.794"/>
                    <measurement group_id="O3" value="-4.35" spread="1.671"/>
                    <measurement group_id="O4" value="-3.92" spread="1.650"/>
                    <measurement group_id="O5" value="-6.25" spread="1.843"/>
                    <measurement group_id="O6" value="4.69" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.45" spread="1.751"/>
                    <measurement group_id="O2" value="-2.30" spread="1.794"/>
                    <measurement group_id="O3" value="-7.25" spread="1.671"/>
                    <measurement group_id="O4" value="-4.05" spread="1.649"/>
                    <measurement group_id="O5" value="-8.81" spread="1.826"/>
                    <measurement group_id="O6" value="3.20" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.37" spread="1.751"/>
                    <measurement group_id="O2" value="-5.68" spread="1.794"/>
                    <measurement group_id="O3" value="-9.33" spread="1.671"/>
                    <measurement group_id="O4" value="-6.12" spread="1.660"/>
                    <measurement group_id="O5" value="-10.91" spread="1.826"/>
                    <measurement group_id="O6" value="0.75" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.61" spread="1.752"/>
                    <measurement group_id="O2" value="-8.28" spread="1.795"/>
                    <measurement group_id="O3" value="-11.26" spread="1.672"/>
                    <measurement group_id="O4" value="-9.78" spread="1.661"/>
                    <measurement group_id="O5" value="-12.04" spread="1.842"/>
                    <measurement group_id="O6" value="0.02" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.71" spread="1.767"/>
                    <measurement group_id="O2" value="-10.01" spread="1.797"/>
                    <measurement group_id="O3" value="-12.63" spread="1.672"/>
                    <measurement group_id="O4" value="-13.03" spread="1.651"/>
                    <measurement group_id="O5" value="-16.68" spread="1.843"/>
                    <measurement group_id="O6" value="-0.33" spread="1.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.71" spread="1.754"/>
                    <measurement group_id="O2" value="-11.96" spread="1.799"/>
                    <measurement group_id="O3" value="-15.46" spread="1.685"/>
                    <measurement group_id="O4" value="-13.72" spread="1.664"/>
                    <measurement group_id="O5" value="-19.59" spread="1.828"/>
                    <measurement group_id="O6" value="-3.03" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.49" spread="1.756"/>
                    <measurement group_id="O2" value="-14.37" spread="1.800"/>
                    <measurement group_id="O3" value="-14.54" spread="1.675"/>
                    <measurement group_id="O4" value="-15.60" spread="1.664"/>
                    <measurement group_id="O5" value="-18.55" spread="1.844"/>
                    <measurement group_id="O6" value="-6.35" spread="1.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.78" spread="1.756"/>
                    <measurement group_id="O2" value="-13.08" spread="1.801"/>
                    <measurement group_id="O3" value="-12.85" spread="1.674"/>
                    <measurement group_id="O4" value="-15.93" spread="1.652"/>
                    <measurement group_id="O5" value="-15.49" spread="1.830"/>
                    <measurement group_id="O6" value="-6.98" spread="1.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.92" spread="1.756"/>
                    <measurement group_id="O2" value="-13.22" spread="1.814"/>
                    <measurement group_id="O3" value="-12.54" spread="1.699"/>
                    <measurement group_id="O4" value="-15.47" spread="1.652"/>
                    <measurement group_id="O5" value="-16.09" spread="1.829"/>
                    <measurement group_id="O6" value="-6.53" spread="1.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.33" spread="1.754"/>
                    <measurement group_id="O2" value="-10.06" spread="1.797"/>
                    <measurement group_id="O3" value="-12.78" spread="1.672"/>
                    <measurement group_id="O4" value="-13.63" spread="1.662"/>
                    <measurement group_id="O5" value="-15.34" spread="1.827"/>
                    <measurement group_id="O6" value="-3.89" spread="1.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.46" spread="1.752"/>
                    <measurement group_id="O2" value="-8.35" spread="1.794"/>
                    <measurement group_id="O3" value="-7.52" spread="1.671"/>
                    <measurement group_id="O4" value="-10.55" spread="1.673"/>
                    <measurement group_id="O5" value="-12.47" spread="1.826"/>
                    <measurement group_id="O6" value="-0.94" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.88" spread="1.780"/>
                    <measurement group_id="O2" value="-6.23" spread="1.794"/>
                    <measurement group_id="O3" value="-5.77" spread="1.671"/>
                    <measurement group_id="O4" value="-6.73" spread="1.661"/>
                    <measurement group_id="O5" value="-9.02" spread="1.826"/>
                    <measurement group_id="O6" value="2.18" spread="1.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.16" spread="1.781"/>
                    <measurement group_id="O2" value="-0.64" spread="1.810"/>
                    <measurement group_id="O3" value="-3.45" spread="1.685"/>
                    <measurement group_id="O4" value="-3.76" spread="1.651"/>
                    <measurement group_id="O5" value="-8.90" spread="1.844"/>
                    <measurement group_id="O6" value="0.70" spread="1.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8</title>
        <description>Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Safety Set included all the participants who received at least 1 dose of study drug. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8</title>
          <description>Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.</description>
          <population>Safety Set included all the participants who received at least 1 dose of study drug. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>picomoles per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.5" spread="122"/>
                    <measurement group_id="O2" value="-20.0" spread="156"/>
                    <measurement group_id="O3" value="-9.9" spread="266"/>
                    <measurement group_id="O4" value="-47.5" spread="170"/>
                    <measurement group_id="O5" value="277.1" spread="429"/>
                    <measurement group_id="O6" value="-28.8" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF</title>
        <description>MSDBP response was defined as the percentage of participants with a MSDBP &lt;90 mmHg or a &gt;=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP &lt;90 mmHg.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF</title>
          <description>MSDBP response was defined as the percentage of participants with a MSDBP &lt;90 mmHg or a &gt;=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP &lt;90 mmHg.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MSDBP Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="34.4"/>
                    <measurement group_id="O5" value="48.8"/>
                    <measurement group_id="O6" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSDBP Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="29.2"/>
                    <measurement group_id="O5" value="45.2"/>
                    <measurement group_id="O6" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF</title>
        <description>MSSBP response was defined as the percentage of participants with a MSSBP &lt;140 mmHg or a &gt;=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP &lt;140 mmHg.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF</title>
          <description>MSSBP response was defined as the percentage of participants with a MSSBP &lt;140 mmHg or a &gt;=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP &lt;140 mmHg.</description>
          <population>FAS population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MSSBP Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="37.6"/>
                    <measurement group_id="O3" value="48.8"/>
                    <measurement group_id="O4" value="34.4"/>
                    <measurement group_id="O5" value="52.4"/>
                    <measurement group_id="O6" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MSSBP Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="40.7"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="44.0"/>
                    <measurement group_id="O6" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test</title>
        <description>The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was &lt;500 nanomoles per liter (nmol/L) at 1 hour after the injection.</description>
        <time_frame>Baseline, 1 hour post-dose at Week 8</time_frame>
        <population>ACTH subset population included all participants prior to treatment with LCI699 and at the end of the treatment interval (Week 8). Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure at the given timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Core Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test</title>
          <description>The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was &lt;500 nanomoles per liter (nmol/L) at 1 hour after the injection.</description>
          <population>ACTH subset population included all participants prior to treatment with LCI699 and at the end of the treatment interval (Week 8). Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure at the given timepoint</population>
          <units>nanomoles per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729.20" spread="123.753"/>
                    <measurement group_id="O2" value="692.74" spread="117.645"/>
                    <measurement group_id="O3" value="604.46" spread="125.017"/>
                    <measurement group_id="O4" value="609.21" spread="107.923"/>
                    <measurement group_id="O5" value="802.32" spread="134.497"/>
                    <measurement group_id="O6" value="822.65" spread="116.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.</description>
        <time_frame>From Week 8 to Week 9</time_frame>
        <population>Randomized Withdrawal Set included all participants with post-baseline blood pressure measurements from Week 8 to Week 9 only. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Withdrawal Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O2">
            <title>Withdrawal Period: LCI699 0.25 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O3">
            <title>Withdrawal Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O4">
            <title>Withdrawal Period: LCI699 0.5 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O5">
            <title>Withdrawal Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O6">
            <title>Withdrawal Period: LCI699 1.0 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O7">
            <title>Withdrawal Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O8">
            <title>Withdrawal Period: LCI699 0.5 mg BID Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O9">
            <title>Withdrawal Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O10">
            <title>Withdrawal Period: Eplerenone 50 mg BID Placebo</title>
            <description>Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O11">
            <title>Withdrawal Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.</description>
          <population>Randomized Withdrawal Set included all participants with post-baseline blood pressure measurements from Week 8 to Week 9 only. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="44"/>
                <count group_id="O9" value="39"/>
                <count group_id="O10" value="36"/>
                <count group_id="O11" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.99"/>
                    <measurement group_id="O2" value="0.5" spread="1.08"/>
                    <measurement group_id="O3" value="1.6" spread="1.01"/>
                    <measurement group_id="O4" value="-0.2" spread="1.09"/>
                    <measurement group_id="O5" value="-0.5" spread="1.03"/>
                    <measurement group_id="O6" value="2.5" spread="1.11"/>
                    <measurement group_id="O7" value="1.3" spread="1.00"/>
                    <measurement group_id="O8" value="1.3" spread="1.02"/>
                    <measurement group_id="O9" value="-1.2" spread="1.06"/>
                    <measurement group_id="O10" value="0.4" spread="1.11"/>
                    <measurement group_id="O11" value="1.6" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP</title>
        <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.</description>
        <time_frame>From Week 8 to Week 9</time_frame>
        <population>Randomized Withdrawal Set included all participants with post-baseline blood pressure measurements from Week 8 to Week 9 only. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Withdrawal Period: LCI699 0.25 mg QD</title>
            <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O2">
            <title>Withdrawal Period: LCI699 0.25 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O3">
            <title>Withdrawal Period: LCI699 0.5 mg QD</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O4">
            <title>Withdrawal Period: LCI699 0.5 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O5">
            <title>Withdrawal Period: LCI699 1.0 mg QD</title>
            <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O6">
            <title>Withdrawal Period: LCI699 1.0 mg QD Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O7">
            <title>Withdrawal Period: LCI699 0.5 mg BID</title>
            <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O8">
            <title>Withdrawal Period: LCI699 0.5 mg BID Placebo</title>
            <description>Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O9">
            <title>Withdrawal Period: Eplerenone 50 mg BID</title>
            <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O10">
            <title>Withdrawal Period: Eplerenone 50 mg BID Placebo</title>
            <description>Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
          <group group_id="O11">
            <title>Withdrawal Period: Placebo</title>
            <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP</title>
          <description>Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.</description>
          <population>Randomized Withdrawal Set included all participants with post-baseline blood pressure measurements from Week 8 to Week 9 only. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="44"/>
                <count group_id="O9" value="39"/>
                <count group_id="O10" value="36"/>
                <count group_id="O11" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.66"/>
                    <measurement group_id="O2" value="3.3" spread="1.80"/>
                    <measurement group_id="O3" value="0.5" spread="1.69"/>
                    <measurement group_id="O4" value="2.5" spread="1.82"/>
                    <measurement group_id="O5" value="0.4" spread="1.72"/>
                    <measurement group_id="O6" value="5.3" spread="1.85"/>
                    <measurement group_id="O7" value="1.6" spread="1.68"/>
                    <measurement group_id="O8" value="4.4" spread="1.69"/>
                    <measurement group_id="O9" value="-1.5" spread="1.79"/>
                    <measurement group_id="O10" value="2.7" spread="1.86"/>
                    <measurement group_id="O11" value="1.8" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: From start of the study drug treatment up to 9 weeks; SAE: From signing of the informed consent up to 9 weeks</time_frame>
      <desc>Core Period: Safety Set included all the participants who received at least 1 dose of study drug. One participant from LCI699 0.5 mg QD was randomized to LCI699 1.0 mg QD and received LCI699 1.0 mg QD, thus was included in this arm in the Safety Set. Withdrawal period: Randomized Withdrawal Safety Set included participants who received at least one dose of the study drug from Week 8 to Week 9.</desc>
      <group_list>
        <group group_id="E1">
          <title>Core Period: LCI699 0.25 mg QD</title>
          <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Core Period: LCI699 0.5 mg QD</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Core Period: LCI699 1.0 mg QD</title>
          <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Core Period: LCI699 0.5 mg BID</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Core Period: Eplerenone 50 mg BID</title>
          <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Core Period: Placebo</title>
          <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Withdrawal Period: LCI699 0.25 mg QD</title>
          <description>Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E8">
          <title>Withdrawal Period: LCI699 0.25 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E9">
          <title>Withdrawal Period: LCI699 0.5 mg QD</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E10">
          <title>Withdrawal Period: LCI699 0.5 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E11">
          <title>Withdrawal Period: LCI699 1.0 mg QD</title>
          <description>Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E12">
          <title>Withdrawal Period: LCI699 1.0 mg QD Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E13">
          <title>Withdrawal Period: LCI699 0.5 mg BID</title>
          <description>Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E14">
          <title>Withdrawal Period: LCI699 0.5 mg BID Placebo</title>
          <description>Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E15">
          <title>Withdrawal Period: Eplerenone 50 mg BID</title>
          <description>Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E16">
          <title>Withdrawal Period: Eplerenone 50 mg BID Placebo</title>
          <description>Participants received eplerenone-matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
        <group group_id="E17">
          <title>Withdrawal Period: Placebo</title>
          <description>Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Skin striae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>8627788300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

